CV

Univ. Prof. Dr. med. Michael Hölzel

Academic education

1996 - 2003: Medical School, Ludwig-Maximilians-University (LMU) Munich

Scientific degrees

6/2004: Medical thesis (Dr. med.), LMU Munich, Summa cum Laude: “Regulation von Teilungswahrscheinlichkeit und Zellzyklusdauer durch das Onkoprotein c-Myc” (Supervisor: Professor Dr. Dirk Eick Helmholtz-Research Center, Munich; Prof. Dr. Wolfram Hörz, Department of Biochemistry, LMU Munich)
3/2003: M.D., Graduation from Medical School, LMU Munich

Scientific career

2019: Appointed as W3 professor and director of the Institute of Experimental Oncology, University Hospital Bonn
2016: Head of liquid biobanking core facility, Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn
2012 - present: Appointment as W2 professor for RNA Biology, Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn (Director Prof. Dr. G. Hartmann)
2007 - 2011: Postdoctoral fellow, The Netherlands Cancer Institute (NKI), Amsterdam, Department of Molecular Carcinogenesis (Group of Professor Rene Bernards, PhD)
2006: Postdoctoral fellow, Helmholtz-Research Center, Munich (Group of Professor Dr. Dirk Eick)
2003 - 2005: Residency in hematology/oncology, Department III for Internal Medicine, Klinikum Grosshadern, LMU Munich (Director Prof. Dr. W. Hiddemann)

Honors/ Awards/ Memberships

2016: Speaker of the BONFOR SciMed MD thesis program
2016 - 2018: Speaker of the Life Science Networking Program "Bonner Forum Biomedizin" (BfB)
2015: Speaker of Bonn NeuroImmunology (BonnNI), MD thesis program funded by the Else-Kröner-Fresenius Foundation
2012: Core member of the DFG excellence cluster ImmunoSensation
2001: Scholarship Harvard-Munich-Alliance (LMU, Munich)
1999: Scholarship Studienstiftung des deutschen Volkes

10 most relevant publications

  • Glodde N*, Bald T*, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, Gebhardt C, Scolyer RA, Long GV, Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T**, Hölzel M**. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity. 2017 Oct 17;47(4):789-802.e9. (*equal contribution; **senior authors)
  • Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol. 2017 Sep;18(9):1004-1015.
  • Reinhardt, J., Landsberg, J., Schmid-Burgk, J. L., Ramis, B. B., Bald, T., Glodde, N., Lopez-Ramos, D., Young, A., Ngiow, S. F., Nettersheim, D., Schorle, H., Quast, T., Kolanus, W., Schadendorf, D., Long, G. V., Madore, J., Scolyer, R. A., Ribas, A., Smyth, M. J., Tumeh, P. C., Tüting, T. & Hölzel, M. MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. Cancer Res. 77, 4697–4709 (2017).
  • Layer, J. P., Kronmüller, M. T., Quast, T., van den Boorn-Konijnenberg, D., Effern, M., Hinze, D., Althoff, K., Schramm, A., Westermann, F., Peifer, M., Hartmann, G., Tüting, T., Kolanus, W., Fischer, M., Schulte, J. & Hölzel, M. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. Oncoimmunology 6, e1320626 (2017).
  • Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D, Kohlmeyer J, Renn M, Phung B, Aymans P, Schmidt T, Hornung V, Davidson I, Goding CR, Jönsson G, Landsberg J, Tüting T, Hölzel M. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun. 2015 Nov 4;6:8755.
  • Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, Gaffal E, Steitz J, Tolba R, Kalinke U, Limmer A, Jönsson G, Hölzel M, Tüting T. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014 Jun;4(6):674-87.
  • Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, Kohlmeyer J, Riesenberg S, van den Boorn-Konijnenberg D, Hömig-Hölzel C, Reuten R, Schadow B, Weighardt H, Wenzel D, Helfrich I, Schadendorf D, Bloch W, Bianchi ME, Lugassy C, Barnhill RL, Koch M, Fleischmann BK, Förster I, Kastenmüller W, Kolanus W, Hölzel M*, Gaffal E*, Tüting T*. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature. 2014 Mar 6;507(7490):109-13. (*co-corresponding authors)
  • Landsberg, J., Kohlmeyer, J., Renn, M., Bald, T., Rogava, M., Cron, M., Fatho, M., Lennerz, V., Wölfel, T., Hölzel, M. & Tüting, T. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490, 412–416 (2012).
  • Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., Groenendijk, F. H., Mittempergher, L., Nijkamp, W., Neefjes, J., Salazar, R., Ten Dijke, P., Uramoto, H., Tanaka, F., Beijersbergen, R. L., Wessels, L. F. A. & Bernards, R. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell 151, 937–950 (2012).
  • Hölzel M*, Huang S*, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, Seeger RC, Messiaen L, Versteeg R, Bernards R. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell. 2010 Jul 23;142(2):218-29. (*equal contribution)

Contact Information

Univ. Prof. Dr. med. Michael Hölzel SFB1399
Univ. Prof. Dr. med. Michael Hölzel

Professor (W3)

University Hospital Bonn

Institute of Experimental Oncology

Curriculum Vitae (CV)

CV